quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:51:55·1556d
NEWSRelease
Osmotica Pharmaceuticals plc logo

Osmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'

OSMT· Osmotica Pharmaceuticals plc
Health Care
Original source

Companies

  • OSMT
    Osmotica Pharmaceuticals plc
    Health Care

Recent analyst ratings

  • Dec 23UpdateHC Wainwright & Co.$5.00
  • Nov 9UpdateJefferies$7.00
  • Sep 24UpdateCantor Fitzgerald$6.00

Related

  • NEWS1555d
    Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
  • SEC1556d
    Osmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR1556d
    Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
  • NEWS1556d
    Osmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25M
  • SEC1557d
    Osmotica Pharmaceuticals plc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
  • PR1557d
    RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
  • PR1569d
    Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
  • NEWS1579d
    54 Biggest Movers From Thursday
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022